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Abstract: The gastrointestinal hormone peptide tyrosine tyrosine 3–36 (PYY3–36) has attained broad
recognition with respect to its involvement in energy homeostasis and the control of food intake. It
is mainly secreted by distal intestinal enteroendocrine L-cells in response to eating and exerts neurally
mediated, paracrine and endocrine effects on various target organs. In addition to its gastrointestinal
effects, PYY3–36 has long been known to inhibit food intake. Recent closer examination of the effects
of PYY3–36 revealed that this gut-derived peptide also influences a wide spectrum of behavioral and
cognitive functions that are pivotal for basic processes of perception and judgment, including central
information processing, salience learning, working memory, and behavioral responding to novelty. Here,
we review the effects of PYY3–36 that go beyond food intake and provide a conceptual framework
suggesting that several apparently unrelated behavioral actions of PYY3–36 may actually reflect different
manifestations of modulating the central dopamine system.
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Abstract	  The	   gastrointestinal	   hormone	   peptide	   tyrosine	   tyrosine	   3-­‐36	   (PYY3-­‐36)	   has	   attained	  broad	  recognition	  with	  respect	  to	  its	  involvement	  in	  energy	  homeostasis	  and	  the	  control	  of	   food	   intake.	   It	   is	   mainly	   secreted	   by	   distal	   intestinal	   enteroendocrine	   L-­‐cells	   in	  response	  to	  eating	  and	  exerts	  both	  neurally	  mediated	  paracrine	  and	  endocrine	  effects	  on	  various	   target	   organs.	   In	   addition	   to	   its	   gastrointestinal	   effects,	   PYY3-­‐36	   has	   long	   been	  known	  to	  inhibit	  food	  intake.	  Recent	  closer	  examination	  of	  the	  effects	  of	  PYY3-­‐36	  revealed	  that	   this	   gut-­‐derived	   peptide	   also	   influences	   a	   wide	   spectrum	   of	   behavioral	   and	  cognitive	   functions	   that	   are	   pivotal	   for	   basic	   processes	   of	   perception	   and	   judgment,	  including	   central	   information	   processing,	   salience	   learning,	   working	   memory,	   and	  behavioral	  responding	  to	  novelty.	  Here,	  we	  review	  the	  effects	  of	  PYY3-­‐36	  that	  go	  beyond	  food	   intake	   and	   provide	   a	   conceptual	   framework	   suggesting	   that	   several	   apparently	  unrelated	  behavioral	  actions	  of	  PYY3-­‐36	  may	  actually	   reflect	  different	  manifestations	  of	  modulating	  the	  central	  dopamine	  system.	  	  	  











1.	  Introduction	  Peptide	   tyrosine	   tyrosine	   (PYY)	   is	   a	  peptide	  hormone	  which,	   together	  with	  pancreatic	  polypeptide	   (PP)	   and	   neuropeptide	   Y	   (NPY),	   comprises	   the	   PP	   family	   of	   peptides	  (Berglund	  et	  al.,	  2003).	  The	  two	  existing	  forms	  of	  PYY	  differ	  by	  two	  amino	  acids	  (Grandt	  et	   al.,	   1994;	  Medeiros	   and	  Turner,	   1994).	   PYY1-­‐36	   is	   released	   from	  enteroendocrine	   L-­‐cells	   in	   response	   to	   nutrient	   signals	   in	   the	   chyme.	   	   In	   the	   blood,	   PYY1-­‐36	   is	   rapidly	  converted	   to	   PYY3-­‐36	   by	   the	   ubiquitously	   expressed	   enzyme,	   dipeptidyl-­‐peptidase	   IV	  (DPP-­‐IV),	  which	  cleaves	  the	  two	  N-­‐terminal	  amino	  acids	  (Mentlein	  et	  al.,	  1993).	  Hence,	  PYY3-­‐36	   is	   the	   major	   circulating	   form	   of	   the	   peptide,	   known	   to	   exert	   different	   and	  sometimes	  opposite	  biological	  functions	  than	  PYY1-­‐36	  (Grandt	  et	  al.,	  1994)	  (Figure	  1).	  	  As	   extensively	   reviewed	   elsewhere	   (Karra	   and	   Batterham,	   2010;	   Schwartz	   and	  Holst,	  2010;	  Walther	  et	  al.,	  2011),	  the	  distinct	  biological	  functions	  exerted	  by	  PYY1-­‐36	  and	  PYY3-­‐36	  have	  been	  explained	  by	  their	  different	  binding	  affinities	   for	   the	   five	  Y	  receptor	  subtypes	   in	   mammals,	   Y1,	   Y2,	   Y4,	   Y5	   and	   Y6.	   	   All	   are	   inhibitory	   G-­‐protein	   coupled	  receptors	  that	  reduce	  cyclic-­‐AMP	  and	  the	  mobilization	  of	  intracellular	  calcium	  (Michel	  et	  al.,	  1998;	  Berglund	  et	  al.,	  2003).	  Whereas	  PYY1-­‐36	  has	  similar	  affinities	  for	  the	  Y1	  and	  Y2	  receptor,	   PYY3-­‐36	   is	   a	   high-­‐affinity	   Y2	   receptor	   ligand	   (Walther	   et	   al.,	   2011).	   In	   the	  periphery,	   the	   Y2	   receptor	   is	   expressed	   by	   parasympathetic	   and	   sympathetic	   sensory	  neurons,	   in	   addition	   to	   intestinal	   and	   some	  vascular	   cells	   (Widdowson,	  1993;	  Gehlert,	  1994;	  Cabrele	  and	  Beck-­‐Sickinger,	  2000).	  The	  Y2	  receptor	  is	  also	  abundantly	  expressed	  in	   several	   regions	   of	   the	   central	   nervous	   system	   (CNS),	   including	   limbic	   and	   cortical	  areas	   (Stanic	   et	   al.,	   2006;	  Walther	   et	   al.,	   2011).	   In	   neuronal	   tissue,	   the	   Y2	   receptor	   is	  localized	   mainly	   presynaptically,	   inhibiting	   neurotransmitter	   release	   upon	   activation	  (Smith-­‐White	   et	   al.,	   2001;	   Stanic	   et	   al.,	   2011).	   Such	   autoreceptor	   functions	   of	   the	   Y2	  receptor	  are	  well	  documented,	  for	  example	  with	  regard	  to	  NPY	  release	  in	  hypothalamic	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areas,	  where	  Y2	  receptor	  agonists	  including	  PYY3-­‐36	  inhibit	  NPY	  synthesis	  and	  secretion	  (King	  et	  al,	  1999;	  Smith-­‐White	  et	  al,	  2001;	  Batterham	  et	  al,	  2002;	  Challis	  et	  al,	  2003).	  PYY	   is	   secreted	   by	  mainly	   distal	   intestinal	   enteroendocrine	   L-­‐cells	   in	   response	   to	  eating,	   and	   plasma	   levels	   of	   PYY3-­‐36	   remain	   elevated	   for	   several	   hours	   after	   meals	  (Adrian	  et	  al.,	  1985;	  Stanley	  et	  al.,	  2004).	  	  The	  best	  known	  functions	  of	  PYY3-­‐36	  are	  in	  the	  gastrointestinal	   system	   where	   it	   regulates	   secretions	   (Yang,	   2002)	   and	   motility	  (Immamura,	   2002).	   Many	   of	   its	   actions	   contribute	   to	   the	   ‘ileal	   brake,’	   whereby	  secretions	  of	  the	  distal	  small	   intestine	  slow	  gastric	  emptying	  when	  nutrients	  reach	  the	  ileum.	  	  	  More	   recently,	   PYY3-­‐36	   has	   attained	   broad	   recognition	   with	   respect	   to	   its	  involvement	   in	   energy	   homeostasis	   and	   the	   control	   of	   food	   intake	   (see	  Manning	   and	  Batterham,	   2014).	   A	   landmark	   study	   by	   Batterham	   et	   al.	   (2002)	   directly	   implicated	  PYY3-­‐36	  in	  the	  physiological	  inhibition	  of	  food	  intake.	  This	  effect	  is	  mediated	  through	  the	  Y2	  receptor	  (Batterham	  et	  al.,	  2002)	  and	  has	  been	  documented	  in	  diverse	  conditions	  and	  several	  species,	  including	  rodents	  and	  humans	  (Table	  1).	  Basal	  levels	  are	  lower	  and	  the	  meal-­‐induced	  release	  of	  PYY3-­‐36	   is	  blunted	   in	  obese	   individuals	   (Alvazrez	  Bartolomé	  et	  al.,	  2002;	  Batterham	  et	  al.,	  2003;	  le	  Roux	  et	  al.,	  2006;	  Guo	  et	  al.,	  Sodowski	  et	  al.,	  2007).	  Also,	   PYY	   overexpression	   protects	   against	   diet-­‐induced	   obesity	   (Boey	   et	   al.,	   2008).	  Importantly,	   PYY3-­‐36	   administration	   reduces	   food	   intake	   similarly	   in	   obese	   and	   non-­‐obese	  subjects	  (Batterham	  et	  al.,	  2003;	  Sloth	  et	  al.,	  2007),	  implying	  that	  obesity	  does	  not	  decrease	  PYY3-­‐36	  sensitivity.	  Collectively,	  these	  observations	  have	  attracted	  considerable	  interest	  in	  PYY3-­‐36	  as	  a	  potential	  pharmacotherapy	  for	  obesity	  (Karra	  et	  al.,	  2009).	  While	  the	  precise	  physiological	  mechanisms	  whereby	  PYY3-­‐36	  inhibits	  eating	  remain	  unclear,	   it	   effectively	   crosses	   the	   blood-­‐brain-­‐barrier	   from	   the	   plasma	   (Nonaka	   et	   al.,	  2003)	   and	   acts	   centrally	   as	   a	   relatively	   selective	   Y2	   receptor	   agonist	   (Grandt	   et	   al.,	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1994).	   Y2	   receptor	   expression	   is	   abundant	   on	   hypothalamic	   arcuate	   neurons	   that	   co-­‐express	   NPY	   and	   agouti-­‐related	   peptide	   (AgrP)	   (Broberger	   et	   al.,	   1997;	   Hahn	   et	   al.,	  1998),	   and	   administration	   of	   PYY3-­‐36	   directly	   into	   the	   Arc	   reduces	   food	   intake	  (Batterham,	  2002).	  Consistent	  with	  its	  action	  as	  an	  inhibitory	  presynaptic	  receptor,	  one	  prevalent	   hypothesis	   suggests	   that	   activation	   of	   the	   Y2	   receptor	   inhibits	   arcuate	   NPY	  neurons	  and	  reduces	  the	  NPY-­‐mediated	  inhibition	  of	  neighboring	  anorexigenic	  neurons	  co-­‐expressing	  pro-­‐opiomelanocortin	   (POMC)	  and	  cocaine-­‐	  and	  amphetamine-­‐regulated	  transcript	  (CART)	  (Broberger	  et	  al.,	  1997;	  Morton	  et	  al.,	  2014).	  	  	  In	   addition	   to	   hypothalamic	   sites	   of	   action,	   there	   are	   also	   alternative	   (but	   not	  mutually	  exclusive)	  mechanisms	  by	  which	  PYY3-­‐36	  could	  inhibit	  food	  intake,	  particularly	  in	   light	  of	   the	  widespread	  expression	  of	  Y2	   receptors	   in	   cortical	   and	   subcortical	  brain	  areas	   (Stanic	   et	   al.,	   2006,	   2011).	   Hence,	   in	   addition	   to	   NPY	   neurons,	   some	   γ-­‐aminobutyric	  acid	  (GABA)	  or	  glutamate	  neurons	  also	  express	  the	  Y2	  receptor	  (Stanic	  et	  al.,	  2006,	  2011).	  Y2	  agonists	  such	  as	  PYY3-­‐36	  may	  thus	  readily	  influence	  neural	  circuits	  in	  diverse	  brain	  regions.	  Consistent	  with	  this,	  using	  functional	  magnetic	  resonance	  imaging	  (fMRI),	   Batterham	   and	   colleagues	   found	   that	   peripheral	   administration	   of	   PYY3-­‐36	  induces	   neuronal	   activation	   in	   several	   brain	   regions,	   including	   target	   areas	   of	   the	  mesolimbic	   and	   nigrostriatal	   dopaminergic	   pathways,	   brainstem	   areas	   including	   the	  nucleus	   tractus	   solitarii	   (NTS),	   and	   cortical	   areas	   including	   the	   orbitofrontal	   cortex	  (Batterham	   et	   al.,	   2007).	   Consistent	   with	   these	   findings,	   our	   research	   group	   also	  observed	  widespread	  neuronal	  activation	  following	  peripheral	  PYY3-­‐36	  administration	  in	  rats	  (Stadlbauer	  et	  al.,	  2013a;	  for	  further	  details,	  see	  Section	  5).	  In	   view	   of	   these	   neuronal	   effects,	   it	   is	   reasonable	   to	   hypothesize	   that	   PYY3-­‐36	   has	  functional	   significance	   in	   the	   brain	   beyond	   its	   role	   in	   controlling	   food	   intake,	   and	  experimental	  research	  in	  rodents	  has	  recently	  begun	  to	  explore	  the	  effects	  of	  PYY3-­‐36	  on	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other	  behaviors.	  Here,	  we	  summarize	  some	  of	  those	  findings	  and	  provide	  a	  conceptual	  framework	   suggesting	   that	   several	   apparently	   unrelated	   behavioral	   actions	   of	   PYY3-­‐36	  actually	  reflect	  different	  manifestations	  of	  modulating	  the	  mesocorticolimbic	  dopamine	  system.	  	  
2.	  PYY3-­‐36	  and	  sensitivity	  to	  psychostimulant	  drugs	  Studies	   in	  both	  humans	  and	  rats	   indicate	   that	   the	  peripheral	  administration	  of	  PYY3-­‐36	  leads	  to	  activation	  of	  central	  dopaminergic	  pathways	  (Batterham	  et	  al.,	  2007;	  Stadlbauer	  et	  al.,	  2013a).	  The	  largest	  populations	  of	  dopamine	  cells	  are	  localized	  in	  two	  neighboring	  midbrain	   nuclei,	   namely	   the	   ventral	   tegmental	   area	   (VTA;	   A10	   cell	   group)	   and	   the	  substantia	  nigra	   (SN;	  A9	  cell	   group)	   (Tzschentke,	  2001;	  Björklund	  and	  Dunnett,	  2007;	  Van	  den	  Heuvel	  and	  Pasterkamp,	  2008).	  The	  majority	  of	  VTA	  dopamine	  cells	  projects	  to	  limbic	   and	   cortical	   areas	   along	   the	  mesolimbic	   and	  mesocortical	   dopamine	   pathways,	  respectively,	  whereas	  a	   large	  part	  of	  the	  nigral	  A9	  dopamine	  cells	   innervate	  the	  dorsal	  striatum	   forming	   the	   nigrostriatal	   dopaminergic	   pathway	   (Figure	   2).	   Midbrain	  dopamine	   cells	   are	   also	   found	   in	   the	   A8	   cell	   group,	   which	   forms	   a	   dorsal	   and	   caudal	  extension	  of	  the	  A9	  cell	  group	  and	  contains	  cells	  that	  project	  to	  both	  striatal,	  limbic	  and	  cortical	   areas	   (Figure	   2).	   A8	   cells	   are	   thus	   an	   integral	   part	   of	   the	   mesolimbic,	  mesocortical,	   and	   nigrostriatal	   dopamine	   pathways	   (Björklund	   and	   Dunnett,	   2007;	  Roeper,	  2013).	  	  	  	  	   Among	   other	   functions,	   the	   mesolimbic	   dopaminergic	   pathway	   is	   important	   in	  mediating	   the	   behavioral	   and	   locomotor	   responses	   to	   drugs	   of	   abuse	   (Soderpalm	   and	  Ericson,	  2013),	  whereas	  the	  nigrostriatal	  pathway	  is	  critically	  involved	  in	  the	  control	  of	  voluntary	   movement	   and	   motor	   stereotypies	   (Groenewegen,	   2003).	   Recent	  neuropharmacological	   investigations	   in	   mice	   demonstrate	   that	   peripheral	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administration	   of	   PYY3-­‐36	   markedly	   modulates	   these	   dopamine-­‐related	   behavioral	  functions	   (Stadlbauer	   et	   al.,	   2014).	   Specifically,	   pretreatment	  with	   PYY3-­‐36	   potentiates	  the	   locomotor	   responses	   to	   subsequent	   amphetamine	   (Amph)	  exposure	  and	   increases	  stereotypical	   behavioral	   reactions	   to	   systemic	   apomorphine	   (Apo)	   (Stadlbauer	   et	   al.,	  2014).	   Amph	   is	   an	   indirect	   dopamine	   receptor	   agonist	   that	   efficiently	   stimulates	  presynaptic	   dopamine	   release	   (Salahpour	   et	   al.,	   2008),	   and	   its	   administration	   elicits	  rigorous	   locomotor	   activity	   (Robinson	   and	   Becker,	   1986).	   Apo	   is	   a	   preferential	  dopamine	  D1/D2	   receptor	   agonist	   that	  dose-­‐dependently	   increases	   locomotor	   activity	  and	   other	   stereotyped	  behaviors	   in	   rodents,	   including	   repetitive	   climbing	   and	   leaning	  (Cabib	   and	   Puglisi-­‐Allegra,	   1985;	   Bitanihirwe	   et	   al.,	   2010).	   The	   mesolimbic	   and	  nigrostriatal	   dopamine	   pathways	   are	   key	   neuronal	   components	   mediating	   the	  behavioral	   responses	   to	   Amph	   and	   Apo.	   Early	   studies	   concluded	   that	   the	   locomotor-­‐enhancing	   effects	   of	   low	   doses	   of	   systemic	   Amph	   result	   from	   increased	   dopamine	  transmission	  in	  the	  NAc	  (Creese	  and	  Iversen,	  1975;	  Pijnenburg	  et	  al.,	  1976),	  particularly	  in	  its	  shell	  sub-­‐region	  (Heidbreder	  and	  Feldon,	  1998).	  More	  recent	  studies	  suggest	  that	  enhanced	  dopamine	  release	  more	  dorsally	  in	  the	  striatum	  contributes	  to	  Amph-­‐induced	  locomotor	  hyperactivity	  as	  well	  (Matthews	  et	  al.,	  2013).	  The	  expression	  of	  stereotyped	  behaviors	   has	   also	   often	   been	   functionally	   linked	   to	   enhanced	   activation	   of	   striatal	  dopamine	  receptors,	  especially	   in	  dorsal	  parts	  of	   the	  striatum	  (Arnt	  et	  al.,	  1988;	  Vasse	  and	   Protais,	   1989;	   Charntikov	   et	   al.,	   2011).	   It	   has	   recently	   been	   found	   that	   PYY3-­‐36	  potentiates	   the	  behavioral	  responses	  to	  both	  Amph	  and	  Apo	  and	  that	   it	   likely	   involves	  increased	   dopaminergic	   activity	   in	   the	   mesolimbic	   and/or	   nigrostriatal	   pathways	  (Stadlbauer	   et	   al.,	   2014).	   Even	   though	   this	   hypothesis	   lacks	   direct	   confirmation,	   it	   is	  consistent	  with	  previous	  ex-­‐vivo	  studies	  reporting	  that	  exogenous	  PYY3-­‐36	  increases	  the	  synthesis	   and	   release	   of	   dopamine	   in	   rat	   striatal	   slices	   (Adewale	   et	   al.,	   2005,	   2007).	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Work	   in	   genetically	   modified	   mice	   lacking	   the	   Y2	   receptor	   has	   provided	   additional	  support	   for	   the	   hypothesis	   that	   signaling	   through	   Y2	   receptors	   can	   exert	   a	   direct	  influence	   on	   striatal	   dopamine	   release	   (Zambello	   et	   al.,	   2011).	   Thus,	   accumulating	  evidence	  suggests	  that	  PYY3-­‐36	  administration	  induces	  neuronal	  (Batterham	  et	  al.,	  2007;	  Stadlbauer	   et	   al.,	   2013a),	   behavioral	   (Stadlbauer	   et	   al.,	   2014),	   and	   neurochemical	  (Adewale	  et	  al.,	  2005,	  2007;	  Zambello	  et	  al.,	  2011)	  changes	  reminiscent	  of	  a	  (transient)	  hyperdopaminergic	  state.	  	  
3.	  PYY3-­‐36	  and	  behavioral	  responses	  to	  novelty	  Responding	  to	  a	  novel	  environment	  engages	  the	  mesolimbic	  dopamine	  system	  (Bardo	  et	  al.,	   1996;	   Blanchard	   et	   al.,	   2009),	   and	   the	   magnitude	   of	   the	   response	   predicts	   the	  behavioral	   responses	   to	   dopaminergic	   psychostimulant	   drugs	   (Marinelli	   and	   White,	  2000).	  Given	  these	  associations,	  it	  has	  been	  hypothesized	  that	  PYY3-­‐36,	  in	  addition	  to	  its	  effects	   on	   potentiating	   psychostimulant	   drug	   sensitivity,	   would	   also	   enhance	   novelty	  seeking.	  In	  support	  of	  this,	  we	  observed	  that	  peripheral	  administration	  of	  PYY3-­‐36	  in	  mice	  increases	  novelty	  seeking	  in	  a	  novel-­‐object	  exploration	  task	  in	  which	  mice	  were	  allowed	  to	  freely	  explore	  an	  unfamiliar	  object	  following	  habituation	  to	  the	  surrounding	  context	  (Stadlbauer	  et	  al.,	  2014).	  These	  effects	  were	  unlikely	  to	  be	  mediated	  by	  possible	  changes	  in	   anxiety-­‐like	   behavior	   because	   identical	   PYY3-­‐36	   treatment	   did	   not	   affect	   behavioral	  indices	  of	  innate	  anxiety	  (Stadlbauer	  et	  al.,	  2013b,	  2014).	  	   More	  likely	  is	  that	  the	  enhancement	  of	  novel	  object	  exploration	  displayed	  by	  PYY3-­‐
36-­‐treated	   animals	   is	   related	   to	   changes	   in	   incentive	   salience.	   Incentive	   salience	   is	   a	  motivational	   attribute	   that	   increases	   the	   attractiveness	   of	   a	   given	   stimulus	   and	  promotes	  approach	  behavior	  towards	  it	  (Berridge	  and	  Robinson,	  1998).	  Research	  in	  rats	  has	   found	  a	  positive	  correlation	  between	   the	  amount	  of	  novelty	   seeking	  and	   incentive	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salience	   attribution	   to	   reward-­‐associated	   cues	   (Beckmann	   et	   al.,	   2011).	   Dopaminergic	  mechanisms	  in	  general,	  and	  increased	  accumbal	  dopaminergic	  activity	  in	  particular,	  are	  critical	   in	   regulating	   the	   perception	   and	   processing	   of	   salient	   stimuli	   (Berridge	   and	  Robinson,	   1998;	   Wise,	   2004).	   For	   example,	   manipulations	   increasing	   and	   decreasing	  dopaminergic	  activity	  in	  the	  NAc,	  respectively,	  enhance	  and	  reduce	  exploratory	  activity	  toward	  novel	  stimuli	  (Rebec	  et	  al.,	  1997;	  Peters	  et	  al.,	  2007;	  Fukushiro	  and	  Frussa-­‐Filho,	  2011;	  Laricchiuta	  et	  al.,	  2014).	  Furthermore,	  rats	  with	  increased	  novelty-­‐seeking	  have	  a	  greater	   behavioral	   sensitivity	   to	   the	   indirect	   dopamine	   receptor	   agonist	   cocaine	  (Beckmann	   et	   al.,	   2011).	   Similar	   parallels	   exist	   following	   peripheral	   PYY3-­‐36	  administration	   in	  mice,	  where	  PYY3-­‐36	   elicits	   a	   concomitant	   increase	   in	   the	   behavioral	  response	   to	   novelty	   and	   to	   Amph	   (Stadlbauer	   et	   al.,	   2014).	   Thus,	   the	   positive	  correlations	   among	   mesolimbic	   dopamine	   activity,	   novelty	   seeking,	   and	   incentive	  salience	   (Bardo	   et	   al.,	   1996;	   Berridge	   and	   Robinson,	   1998;	   Blanchard	   et	   al.,	   2009;	  Beckmann	  et	  al.,	  2011)	  all	  suggest	  that	  PYY3-­‐36-­‐induced	  potentiation	  of	  novelty	  seeking	  likely	  involves	  increased	  incentive	  salience	  attribution	  to	  the	  novel	  stimuli.	  	   The	   same	   processes	   may	   also	   explain	   the	   recently	   reported	   decreases	   in	   social	  approach	   behavior	   following	   peripheral	   PYY3-­‐36	   administration	   in	  mice	   (Stadlbauer	   et	  al.,	  2013b).	  When	  given	  the	  choice	  between	  exploring	  an	  unfamiliar	  mouse	  and	  a	  novel	  inanimate	   object,	  mice	   (like	  most	   other	   rodents)	   typically	   prefer	   spending	  more	   time	  with	  the	  live	  mouse	  relative	  to	  the	  inanimate	  object	  (Moy	  et	  al.	  2008;	  Vuillermot	  et	  al.,	  2011).	   Following	   PPY3-­‐36	   treatment,	   however,	   the	   preference	   is	   no	   longer	   seen,	   and	  PYY3-­‐36-­‐treated	  mice	  spend	  more	  time	  with	   the	  novel	  object	  at	   the	  expanse	  of	  reduced	  time	  spent	  with	  the	   live	  mouse	  (Stadlbauer	  et	  al.,	  2013b).	  Consistent	  with	  this,	  genetic	  ablation	  or	  pharmacological	  inhibition	  of	  the	  Y2	  receptor	  causes	  an	  opposite	  pattern	  of	  effects,	  including	  increased	  social	  approach	  behavior	  (Karl	  et	  al.,	  2010;	  Morales-­‐Medina	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et	   al,	   2012).	   Hence,	   stimulation	   or	   attenuation	   of	   Y2	   receptor	   signaling	   reduces	   or	  increases	  social	  approach	  behavior,	  respectively,	  and	  these	  effects	  may	  at	  least	  partially	  involve	  altered	   incentive	   salience	  attribution	   to	  unfamiliar	   congenic	   species	  and	  novel	  inanimate	  objects.	  	  
4.	  PYY3-­‐36	  and	  central	  information	  processing	  Aberrant	   salience	   processing	   is	   also	   involved	   in	   the	   disruption	   of	   central	   information	  processing,	  especially	  when	  the	  brain	  is	  required	  to	  discriminate	  between	  relevant	  and	  irrelevant	  stimuli	  (Smith	  et	  al.,	  2006;	  Winton-­‐Brown	  et	  al.,	  2014).	  Under	  such	  conditions,	  increased	  mesolimbic	  dopamine	  activity	  enhances	  the	  salience	  of	  irrelevant	  stimuli,	  and	  as	   a	   consequence	   the	   organism	   often	   fails	   to	   differentiate	   between	   relevant	   and	  irrelevant	   information	   (Kapur,	   2003;	   Smith	   et	   al.,	   2006).	   The	   essence	   of	   this	  phenomenon	  can	  be	  captured	  by	  a	  behavioral	  paradigm	  known	  as	  latent	  inhibition	  (LI),	  a	   model	   of	   associative	   learning	   in	   which	   non-­‐reinforced	   pre-­‐exposures	   to	   a	   to-­‐be-­‐conditioned	  stimulus	  (CS)	  retard	  subsequent	  conditioning	  between	  the	  same	  CS	  and	  the	  unconditioned	   stimulus	   (US)	   (Lubow	   and	   Moore,	   1959;	   Lubow,	   2005).	   Prevalent	  neuropsychological	   theories	   posit	   that	   LI	   is	   caused	   by	   the	   development	   of	   selective	  attention	  away	  from	  the	  pre-­‐exposed	  stimulus,	  so	  that	  non-­‐reinforced	  CS	  pre-­‐exposure	  diminishes	   the	   perceived	   salience	   of	   the	   CS	   during	   conditioning	   (Mackintosh,	   1975;	  Lubow	  et	  al.,	  1981;	  for	  other	  neuropsychological	  theories,	  see	  Weiner,	  2003	  and	  Lubow,	  2005).	  LI	  is	  often	  referred	  to	  as	  a	  form	  of	  “salience	  learning”	  (Young	  et	  al.,	  2005;	  Nelson	  et	   al.,	   2011),	   and	   its	   expression	   is	   taken	   as	   index	   of	   the	   tendency	   of	   an	   organism	   to	  successfully	  ignore	  stimuli	  that	  historically	  predict	  no	  significant	  consequences	  (Weiner,	  2003).	   Aberrant	   salience	   attribution	   to	   inconsequential	   stimuli	   weakens	   LI,	   and	   is	  indicative	  of	  a	  susceptibility	  to	  distraction	  by	  irrelevant	  information.	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   Similar	   types	   of	   central	   information	   processing	   can	   also	   be	   assessed	   using	  behavioral	   paradigms	   that	   do	   not	   involve	   explicit	   associative	   learning	   processes.	   One	  widely	  used	  example	  is	  prepulse	  inhibition	  (PPI)	  of	  the	  acoustic	  startle	  reflex,	  which	  is	  the	  reduction	  of	  a	  startle	  reaction	  to	  a	  startle-­‐eliciting	  stimulus	  (pulse)	  when	  it	  is	  shortly	  preceded	  by	  a	  weak	  stimulus	  (prepulse)	  (Hoffman	  and	  Searle,	  1965;	  Braff	  et	  al.,	  2001).	  PPI	   provides	   an	   operational	   measure	   of	   sensorimotor	   gating,	   in	   which	   central	   gating	  mechanisms	  protect	  the	  processing	  of	  the	  information	  contained	  in	  the	  initial	  prepulse	  from	  distraction	  by	  the	  subsequent	  pulse	  stimulus	  (Graham,	  1975;	  Braff	  et	  al.,	  2001).	  PPI	  thus	   serves	   to	   filter	   or	   gate	   intrusive	   sensorimotor	   information.	   Disruption	   of	   such	  gating	  mechanisms	  can	  lead	  to	  central	  stimulus	  overload	  and	  associated	  dysfunctions	  in	  allocating	   the	   limited	   neuronal	   resources	   to	   only	   the	   most	   important	   stimuli	  encountered	  in	  the	  environment	  (Swerdlow	  et	  al.,	  2000;	  Braff	  et	  al.,	  2001).	  	   As	  extensively	  reviewed	  elsewhere	  (Swerdlow	  et	  al,	  2000;	  Braff	  et	  al.,	  2001;	  Weiner,	  2003;	   Lubow,	   2005;	   Young	   et	   al.,	   2005),	   experimental	   manipulations	   or	   pathological	  conditions	   that	   result	   in	   increased	  mesolimbic	   dopamine	   activity	   disrupt	   both	   LI	   and	  PPI.	   Weakening	   of	   PPI	   and	   LI	   can	   arise	   from	   manipulations	   that	   directly	   target	   the	  central	   dopamine	   system,	   such	   as	   administering	  Amph	  or	  Apo	   (Swerdlow	  et	   al,	   2000;	  Braff	  et	  al.,	  2001;	  Weiner,	  2003;	  Lubow,	  2005;	  Young	  et	  al.,	  2005).	  Alternatively,	  PPI	  and	  LI	   deficiency	   can	   also	   be	   induced	   by	   manipulations	   that	   do	   not	   primarily	   target	   the	  central	   dopamine	   system,	   but	   instead	   lead	   to	   down-­‐stream	   increases	   in	   mesolimbic	  dopamine	   signaling	   (Meyer	   and	   Feldon,	   2009;	   Peleg-­‐Raibstein	   et	   al.,	   2012).	   Hence,	  increased	  mesolimbic	   dopamine	   signaling	   is	   a	   common	  neurochemical	  mechanism	   for	  the	   disruption	   of	   PPI	   and	   LI,	   regardless	   of	  whether	   the	   experimental	  manipulation	   or	  pathological	  condition	  directly	  or	  indirectly	  affects	  the	  mesolimbic	  dopamine	  pathways.	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5.	  PYY3-­‐36	  and	  cognition	  Signaling	  at	  the	  Y2	  receptor	  has	  been	  further	  implicated	  in	  certain	  types	  of	  learning	  and	  memory	   (Borbély	   et	   al.,	   2013),	   with	   most	   data	   suggesting	   that	   activation	   of	   the	   Y2	  receptor	  has	  beneficial	  effects	  on	  long-­‐term	  memory.	  For	  example,	  Redrobe	  et	  al.	  (2004)	  found	   that	   mice	   lacking	   the	   Y2	   receptor	   have	   a	   selective	   impairment	   in	   long-­‐term	  retention	   of	   spatial	   memory	   and	   long-­‐term	   memory	   for	   objects.	   Similar	   effects	   were	  observed	   following	   acute	   pharmacological	   blockade	   of	   the	   Y2	   receptor	   in	   mice	   (dos	  Santos	   et	   al,	   2013).	   Y2	   receptor	   signaling	   has	   also	   been	   implicated	   in	   short-­‐term	  memory,	  but	  in	  contrast	  to	  its	  detrimental	  effects	  on	  long-­‐term	  memory,	  attenuation	  of	  Y2	   signaling	   exerts	   beneficial	   effects	   on	   short-­‐term	  memory	   (Gonçalves	   et	   al.,	   2012).	  This	  “double-­‐edged	  sword”	  effect	  of	  facilitating	  long-­‐term	  memory	  but	  impeding	  short-­‐term	  memory	  is	  consistent	  with	  a	  dual-­‐process	  model	  of	  memory,	   in	  which	  short-­‐term	  and	  long-­‐term	  memory	  are	  separate	  and	  sometimes	  competing	  processes	  (Sanderson	  et	  al.,	  2009;	  Sanderson	  and	  Bannerman,	  2012).	  	   When	  we	  directly	  examined	  the	  effects	  of	  PYY3-­‐36	  on	  learning	  and	  memory,	  we	  found	  	  that	  intraperitoneal	  PYY3-­‐36	  administration	  markedly	  impaired	  working	  memory	  in	  mice	  (Stadlbauer	  et	  al.,	  2013b).	  Working	  memory	  refers	  to	  a	  short-­‐term	  memory	  buffer	  used	  to	   hold	   relevant	   information	   temporarily	   active	   in	   order	   to	   guide	   on-­‐going	   behavior	  (Baddeley,	   2003).	   Hence,	   the	   negative	   influence	   of	   PPY3-­‐36	   on	   working	   memory	   is	  consistent	  with	  the	  concept	  that	  activation	  of	  Y2	  receptor	  signaling	  impedes	  short-­‐term	  forms	  of	  memory	  (Gonçalves	  et	  al.,	  2012).	  	   Successful	  performance	  in	  working	  memory	  tests	  depends	  on	  several	  factors.	  First,	  the	  test	  subject	  must	  allocate	  appropriate	  attention	  to	  the	  relevant	  stimuli,	  both	  during	  the	   initial	   acquisition	   (learning)	   trial	   and	   subsequent	   expression	   (memory)	   trials.	  Second,	   the	   subject	   must	   retrieve	   the	   relevant	   short-­‐term	   information	   based	   on	   its	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previous	  action	  during	  the	  acquisition	  pause	  in	  order	  to	  effectively	  complete	  the	  task	  on	  a	  subsequent	  memory	  trial.	  This	  cognitive	  demand	  is	  further	  dependent	  on	  the	  amount	  of	   experienced	  proactive	   interference,	  which	  occurs	  when	  cognitive	  processing	  during	  (multiple)	   acquisition	   trials	   negatively	   affects	   performance	   on	   subsequent	   test	   trials	  (Hartshorne,	   2008).	  Hence,	   there	   are	   several	   potential	   neurocognitive	  mechanisms	  by	  which	  PYY3-­‐36	  could	  disrupt	  working	  memory.	  In	  view	  of	  the	  marked	  effects	  of	  PYY3-­‐36	  on	  salience	   processing	   and	   selective	   attention	   (see	   Section	   4),	   it	   seems	   feasible	   that	  attentional	   deficits	   are	   involved.	   This	   interpretation	   would	   also	   be	   consistent	   with	  recent	   reports	   that	   working	   memory	   performance	   positively	   correlates	   with	   central	  information	   processing	   capacity	   (Singer	   et	   al.,	   2013),	   both	   of	   which	   are	   reduced	   by	  peripheral	  PYY3-­‐36	  administration	  in	  mice	  (Stadlbauer	  et	  al.,	  2013b).	  	  
6.	   Modulation	   of	   GABA-­‐dopamine	   interactions	   by	   PYY3-­‐36:	   A	   common	  
pathway	  for	  diverse	  behavioral	  changes?	  As	   detailed	   above,	   studies	   from	   PPY3-­‐36-­‐treated	  mice	   (Stadlbauer	   et	   al.,	   2013b,	   2014),	  complemented	  by	  studies	  using	  Y2	  receptor-­‐deficient	  mice	  or	  preferential	  Y2	  receptor	  antagonists	  (Redrobe	  et	  al.,	  2004;	  Karl	  et	  al.,	  2010;	  Zambello	  et	  al.,	  2011;	  Gonçalves	  et	  al.,	  2012;	   Morales-­‐Medina	   et	   al,	   2012),	   document	   that	   PYY3-­‐36	   modulates	   behavioral	   and	  cognitive	  activities	  in	  addition	  to	  simply	  reducing	  food	  intake.	  An	  important	  question	  is	  whether	  the	  diverse	  repertoire	  of	  neurobehavioral	  and	  neurocognitive	  changes	  involves	  different	   neuronal	   and	   neurochemical	   processes,	   or	  whether	   it	   can	   be	   explained	   by	   a	  common	  neuronal	  mechanism.	  	   In	  support	  of	  the	  latter,	  many	  of	  the	  behavioral	  functions	  influenced	  by	  PYY3-­‐36	  are	  critically	   regulated	   by	   subcortical	   dopamine	   activity.	   These	   include	   Amph-­‐induced	  locomotor	   hyperactivity	   (Robinson	   and	   Becker,	   1986;	   Heidbreder	   and	   Feldon,	   1998),	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Apo-­‐induced	   behavioral	   stereotypies	   (Arnt	   et	   al.,	   1988;	   Vasse	   and	   Protais,	   1989;	  Charntikov	   et	   al.,	   2011),	   novelty	   seeking	   (Bardo	   et	   al.,	   1996;	   Berridge	   and	   Robinson,	  1998;	  Blanchard	  et	  al.,	  2009),	  sensorimotor	  gating	  (Swerdlow	  et	  al.,	  2000,	  2001;	  Braff	  et	  al.,	   2001),	   and	   selective	   attention	   and	   salience	   learning	   (Weiner,	   2003;	   Young	   et	   al.,	  2005),	  all	  of	  which	  are	  changed	  by	  peripheral	  PYY3-­‐36	  administration	  (Stadlbauer	  et	  al.,	  2013b;	   2014).	   Hence,	   the	   central	   pro-­‐dopaminergic	   effects	   of	   PYY3-­‐36	   may	   provide	   a	  common	  mechanism	  underlying	   the	   induction	   of	   different	   behavioral	   alterations.	   This	  interpretation	   fits	   with	   the	   general	   proposition	   that	   a	   core	   disruption	   in	   a	   key	  neurotransmitter	   system	   can	   give	   rise	   to	   diverse	   behavioral	   and	   cognitive	   alterations	  (Meyer	  and	  Feldon,	  2009,	  2010).	  Consistent	  with	  this,	  many	  clinical	  behavioral	  disorders	  involve	   abnormally	   enhanced	   dopamine	   activity	   (Kapur,	   2003;	   Winton-­‐Brown	   et	   al.,	  2014).	  	  	   Given	  the	  importance	  of	  dopamine	  for	  so	  many	  behaviors,	  and	  the	  observation	  that	  PYY3-­‐36	   influences	   dopamine	   functioning,	   the	   determination	   of	   how	   PYY3-­‐36	   influences	  dopamine	   signaling	   is	   an	   important	   goal.	  Available	  data	   suggest	   that	  PYY3-­‐36	   increases	  striatal	   dopamine	   release	   via	   a	   presynaptic	  modulation	   of	   dopamine	   release	   in	   target	  areas	  rather	  than	  from	  a	  direct	  action	  on	  midbrain	  dopamine	  cell	  activity	  per	  se	  (Figure	  
3).	   Double	   immunoenzyme	   staining	   of	   the	   neuronal	   early	   gene	   product	   c-­‐Fos	   and	   the	  dopaminergic	   marker	   tyrosine	   hydroxylase	   (TH)	   revealed	   that	   peripheral	   PYY3-­‐36	  treatment	  does	  not	  activate	  TH-­‐positive	  dopamine	  cells	  in	  the	  VTA	  or	  SNc	  (Stadlbauer	  et	  al.,	  2014).	  It	  does,	  however,	  induce	  neuronal	  activation	  in	  ventral	  (NAc)	  and	  dorsal	  (CPu)	  parts	   of	   the	   striatum	   (Stadlbauer	   et	   al.,	   2014),	   which	   are	   the	   two	   primary	   areas	  innervated	   by	   VTA	   and	   SNc	   dopaminergic	   neurons	   (Van	   den	  Heuvel	   and	   Pasterkamp,	  2008).	  Hence,	  striatal	  neuronal	  activation	  following	  PYY3-­‐36	  treatment	  can	  emerge	  in	  the	  absence	  of	  direct	  activation	  of	  the	  mesoaccumbal	  (VTA	  to	  NAc)	  or	  nigrostriatal	  (SNc	  to	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CPu)	  dopaminergic	  pathways.	   Consistent	  with	   this,	   ex-­‐vivo	  pharmacological	   studies	   in	  rat	   brain	   striatal	   slices	   demonstrated	   that	   PYY3-­‐36	   increases	   dopamine	   release	   even	  though	   the	   dopaminergic	   axon	   terminals	   were	   disconnected	   from	   their	   cell	   bodies	  (Adewale	  et	  al.,	  2007).	  Y2	   receptors	   are	   localized	   presynaptically	   where	   they	   inhibit	   neurotransmitter	  release	  (Smith-­‐White	  et	  al.,	  2001;	  Stanic	  et	  al.,	  2006).	  This	  has	  been	  well	  documented	  for	  hypothalamic	   NPY	   release,	   where	   Y2	   agonists	   including	   PYY3-­‐36	   inhibit	   NPY	   synthesis	  and	  secretion	  (King	  et	  al,	  1999;	  Smith-­‐White	  et	  al,	  2001;	  Batterham	  et	  al,	  2002;	  Challis	  et	  al,	  2003).	  The	  Y2	  receptor	  is	  also	  abundantly	  expressed	  in	  the	  striatum	  and	  many	  other	  subcortical	  structures	  (Stanic	  et	  al.,	  2006).	  Interestingly,	  however,	  this	  expression	  seems	  to	   be	   restricted	   to	   non-­‐dopaminergic	   cells	   and	   fibers,	   as	   presynaptic	   dopaminergic	  terminals	  lack	  a	  clear	  expression	  of	  Y2	  receptors	  (Stanic	  et	  al.,	  2011).	  The	  implication	  is	  that	  any	  modulation	  of	  striatal	  dopamine	  release	  by	  PYY3-­‐36	  is	  unlikely	  to	  involve	  direct	  Y2	   signaling	   at	   dopaminergic	   fibers.	   Instead,	   it	   may	   be	   largely	   driven	   by	   other	  neurotransmitter	   systems	   that	   are	   functionally	   connected	   to	   presynaptic	   dopamine	  terminals.	   In	   particular,	   PYY3-­‐36	   may	   activate	   Y2	   receptors	   expressed	   on	   striatal	  GABAergic	  interneurons,	  which	  in	  turn	  can	  robustly	  attenuate	  striatal	  dopamine	  release	  by	   providing	   inhibitory	   inputs	   to	   presynaptic	   dopamine	   terminals	   (Smith	   and	   Kieval,	  2000;	  David	  et	  al.,	  2005).	  Since	  activation	  of	  Y2	  receptors	  induces	  neuronal	  inhibition,	  it	  can	   be	   expected	   that	   PYY3-­‐36-­‐induced	   activation	   of	   these	   receptors	   inhibits	   neuronal	  activity	  of	  striatal	  GABAergic	  interneurons	  (Acuna-­‐Goycolea	  et	  al.,	  2005;	  see	  also	  Figure	  
3).	   Such	   inhibition	  would,	   in	   turn,	  weaken	   the	   inhibitory	   inputs	   of	   striatal	   GABAergic	  interneurons	   onto	   presynaptic	   dopamine	   terminals,	   thereby	   facilitating	   the	   release	   of	  dopamine	   (Figure	   3).	   Hence,	   PYY3-­‐36	   may	   induce	   its	   pro-­‐dopaminergic	   effects	   by	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weakening	   the	   fast-­‐forward	   inhibition	   of	   presynaptic	   dopaminergic	   fibers	   by	   striatal	  GABAergic	  interneurons.	  	  	  Consistent	   with	   this,	   both	   human	   imaging	   studies	   (Batterham	   et	   al.,	   2007)	   and	  immunohistochemical	   findings	   in	   mice	   (Stadlbauer	   et	   al.,	   2014)	   indicate	   that	   PYY3-­‐36	  induces	  neuronal	  activation	  in	  striatal	  areas,	  and	  leads	  to	  increased	  neuronal	  activity	  in	  down-­‐stream	  brain	  areas	  that	  are	  directly	  innervated	  by	  striatal	  neurons,	  including	  the	  ventral	  palladium	  (VP)	  (Stadlbauer	  et	  al.,	  2014).	  The	  VP	  is	  a	  primary	  projection	  site	  of	  the	   ventral	   striatum	   (Groenewegen	   et	   al.,	   1996;	   Groenewegen,	   2003)	   and	   has	   been	  implicated	   in	   behavioral	   functions	   that	   are	   affected	   by	   exogenous	   PYY3-­‐36	   treatment,	  including	  sensorimotor	  gating	  (Kodsi	  and	  Swerdlow,	  1995;	  Kretschmer	  and	  Koch,	  1998),	  behavioral	   sensitivity	   to	   dopamine-­‐stimulating	   drugs	   such	   as	   Amph	   (Swerdlow	   and	  Koob,	  1987;	  Mele	  et	  al.,	  1998),	  and	   incentive	  salience	  attribution	  (Tindell	  et	  al.,	  2005).	  The	   general	   consensus	   is	   that	   these	   behavioral	   and	   neuropsychological	   functions	   are	  markedly	   affected	   by	   increased	   VP	   activity	   similarly	   to	   what	   has	   been	   observed	  following	  peripheral	  PYY3-­‐36	  administration	  (Stadlbauer	  et	  al.,	  2013b,	  2014).	  	  It	  is	  likely	  that	  PYY3-­‐36-­‐induced	  suppression	  of	  GABAergic	  activity	  is	  not	  restricted	  to	  striatal	  areas	  (Acuna-­‐Goycolea	  et	  al.,	  2005),	  which	  in	  turn	  may	  have	  functional	  relevance	  as	   well.	   For	   example,	   working	   memory	   is	   dependent	   on	   the	   integrity	   of	   GABAergic	  signaling,	  especially	  in	  cortical	  structures	  such	  as	  the	  PFC	  (Lewis	  et	  al.,	  2005;	  Lewis	  and	  Moghaddam,	   2006).	   GABA-­‐mediated	   inhibition	   is	   an	   essential	   component	   in	   the	  synchronization	   of	   neuronal	   rhythms	   and	   oscillatory	   activity	   (Lewis	   et	   al.,	   2005;	  Kohl	  and	  Paulsen,	  2010),	  and	  these	  in	  turn	  are	  important	  for	  working	  memory	  (Lewis	  et	  al.,	  2005;	  Lewis	  and	  Moghaddam,	  2006).	  According	  to	  the	  prevailing	  view,	  reduced	  activity	  of	  cortical	  GABAergic	  interneurons	  leads	  to	  reduced	  peri-­‐somatic	  inhibition	  of	  excitatory	  pyramidal	  cells,	  and	  consequently	  impairs	  the	  synchronized	  excitatory	  neural	  response	  
18	  
	  
that	   is	   required	   for	  optimal	  working	  memory	   functions	   (Lewis	   et	   al.,	   2005;	  Lewis	   and	  Moghaddam,	   2006;	   Kohl	   and	   Paulsen,	   2010).	   It	   is	   unknown	  whether	   and/or	   to	   what	  extent	  PYY3-­‐36	  could	  interfere	  with	  such	  neuronal	  synchronization	  processes.	  Given	  that	  PYY3-­‐36	  can	  efficiently	  reduce	  GABAergic	  activity	  (Acuna-­‐Goycolea	  et	  al.,	  2005),	  however,	  interference	   with	   GABA-­‐mediated	   neuronal	   synchronization	   may	   offer	   a	   plausible	  mechanism	  by	  which	  PYY3-­‐36	  disrupts	  working	  memory	  (Stadlbauer	  et	  al.,	  2013b).	  	  
	  
7.	  Effects	  of	  PYY3-­‐36	  on	  food	  intake	  and	  other	  behaviors:	  Separate	  functional	  
entities	  or	  pieces	  of	  the	  same	  puzzle?	  Activation	  of	  the	  Y2	  receptor	  by	  PYY3–36	  has	  thus	  far	  mostly	  been	  studied	  with	  respect	  to	  the	   control	   of	   food	   intake	   and	   regulation	   of	   energy	   homeostasis	   (Chandarana	   and	  Batterham,	   2008;	   Neary	   and	   Batterham,	   2009).	   Although	   some	   of	   these	   studies	   also	  looked	   at	   brain	   areas	   involved	   in	   the	   hedonic	   control	   of	   eating	   (e.g.,	   Batterham	   et	   al.,	  2007),	  most	  of	  them	  focused	  on	  PYY3–36’s	  effect	  on	  homeostatic	  brain	  regions	  such	  as	  the	  hypothalamus	   (Broberger	   et	   al.,	   1997;	   Hahn	   et	   al.,	   1998).	   As	   summarized	   in	   the	  preceding	   sections,	   however,	   there	   is	   increasing	   evidence	   that	   PYY3-­‐36	   modulates	  numerous	  other	  behavioral	  and	  cognitive	  functions	  beyond	  eating	  and	  activates	  a	  broad	  spectrum	   of	   brain	   regions	   and	   neurotransmitter	   systems.	   This	   raises	   the	   intriguing	  question	   as	   to	   whether	   the	   effects	   of	   PYY3-­‐36	   on	   food	   intake	   and	   other	   behaviors	  represent	   distinct	   and	   independent	   behavioral	   processes,	   or	   whether	   they	   may	   be	  somehow	  interrelated.	  	  Current	   knowledge	   does	   not	   readily	   allow	   for	   an	   evidence-­‐based	   answer	   to	   this	  question.	   There	   are,	   however,	   a	   number	   of	   potential	   neural	   and	   neuropsychological	  processes	   that	   could	   provide	   a	   link	   between	   the	   PYY3-­‐36-­‐induced	   inhibition	   of	   food	  intake	   and	   other	   functional	   changes	   in	   seemingly	   distinct	   behavioral	   domains.	   One	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possible	  link	  relates	  to	  the	  role	  of	  dopamine	  in	  reward	  and	  incentive	  values	  on	  the	  one	  hand,	   and	   to	   the	   associations	  between	   reward	   and	   eating	  behavior	   on	   the	   other	  hand	  (Hnaskoa	   et	   al.,	   2004).	   These	   functional	   associations	   are	   highly	   complex	   and	   likely	  involve	  intricate	  interactions	  among	  homeostatic,	  hedonic,	  motivational,	  and	  associative	  processes	   (Berthoud	  et	   al.,	   2011;	  Glimcher,	   2011;	  Kenny,	   2011;	   Salamone	   and	  Correa,	  2012;	   Richard	   et	   al.,	   2013;	   Morton	   et	   al.,	   2014).	   As	   part	   of	   these	   interactions,	   it	   is	  becoming	  increasingly	  evident	  that	  dopamine	  signaling	  cannot	  simply	  be	  equated	  with	  hedonic	  experience,	  i.e.,	  the	  feeling	  of	  pleasure.	  Indeed,	  many	  studies	  cast	  doubt	  on	  the	  “common	  dopamine	  hypothesis	  of	  reward”	  concept,	  which	  in	  essence	  suggests	  that	  the	  experience	  of	  pleasure	  positively	  correlates	  with	  mesolimbic	  dopaminergic	  activity	  (for	  a	   detailed	   discussion,	   see	   Salamone	   and	   Correa,	   2012;	   Richard	   et	   al.,	   2013).	   It	   may	  therefore	   also	   be	   questioned	   whether	   excessive	   food	   intake	   necessarily	   reflects	   an	  attempt	   to	   generate	  more	   reward	   in	   compensation	   for	   reduced	  mesolimbic	   dopamine	  signaling	  (Pothos	  et	  al.,	  1998;	  Blum	  et	  al.,	  2000;	  Volkow	  and	  Wise,	  2005;	  Volkow	  et	  al.,	  2008).	   The	   mirror	   image	   of	   this	   proposition	   implies	   that	   increases	   in	   mesolimbic	  dopamine	   activity	   would	   lead	   to	   an	   inhibition	   of	   food	   intake	   because	   sufficient	  dopamine	  signaling	  suppresses	  the	  further	  need	  of	  more	  hedonic	  value	  associated	  with	  food	   intake.	  Whether	  or	  not	   such	  hedonic	  processes	   offer	   a	  possible	   link	  between	   the	  PYY3-­‐36-­‐induced	  enhancement	  of	  striatal	  dopamine	  activity	  and	  inhibition	  of	  food	  intake	  is	   currently	   unknown.	   In	   view	   of	   the	   emerging	   limitations	   of	   the	   “common	   dopamine	  hypothesis	  of	  reward”	  (Salamone	  and	  Correa,	  2012),	  however,	  we	  believe	  that	  this	  link	  cannot	  simply	  be	  explained	  by	  a	  dopamine-­‐mediated	  modification	  of	  the	  hedonic	  value	  of	   food.	   Rather,	   we	   agree	   with	   the	   rich	   literature	   suggesting	   that	   immediate	   and	  unpredicted	   hedonic	   experiences	   (“liking”)	   are	   linked	   only	   minimally	   to	   mesolimbic	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dopamine	  signaling,	  and	   instead	  are	  more	  directly	  associated	  with	  and	  precipitated	  by	  opioidergic	  signals	  (Berridge	  et	  al.,	  2009;	  Richard	  et	  al.,	  2013).	  	   In	  contrast	  to	  its	  limited	  influence	  on	  “liking,”	  mesolimbic	  dopamine	  signaling	  likely	  plays	   a	   crucial	   role	   in	   “wanting,”	   which	   in	   relation	   to	   food	   intake	   is	   typically	  conceptualized	   as	   incentive	   salience	   (Berridge	   et	   al.,	   2009).	   Incentive	   salience	   in	   this	  case	   is	   a	   type	   of	   motivation	   that	   promotes	   approach	   toward	   and	   consumption	   of	  rewards,	  and	  is	  largely	  mediated	  by	  subcortical	  neural	  systems	  that	  include	  mesolimbic	  dopamine	  projections	  (Berridge	  et	  al.,	  2009;	  Richard	  et	  al.,	  2013).	  Notably,	  “wanting”	  can	  apply	   to	   innate	   (unconditioned)	   incentive	   stimuli	   or	   to	   conditioned	   stimuli	   that	  were	  originally	  neutral	  but	  now	  predict	   the	  availability	  of	   rewarding	  stimuli	   following	  prior	  conditioning	   with	   an	   innate	   incentive	   stimulus	   (Berridge,	   2007).	   Depending	   on	   the	  context,	   “wanting”	   can	   thus	   be	   precipitated	   by	   various	   neuropsychological	   processes,	  including	  appetitive	  motivation,	  approach	  behavior,	  reward	  prediction,	  and	  exertion	  of	  effort	  (Berridge,	  2007;	  Berridge	  et	  al.,	  2009;	  Salamone	  and	  Correa,	  2012;	  Richard	  et	  al.,	  2013).	   Considering	   these	   multiple	   possibilities,	   it	   seems	   obvious	   that	   the	   role	   of	  dopamine	   in	   “wanting”	   is	   multifaceted.	   As	   extensively	   reviewed	   elsewhere	   (Berridge,	  2007;	  Berridge	  et	  al.,	  2009;	  Salamone	  and	  Correa,	  2012;	  Richard	  et	  al.,	  2013),	  however,	  it	   appears	   that	   striatal	   dopamine	   activity	   generally	   promotes	   many	   of	   the	  neuropsychological	   mechanisms	   underlying	   “wanting”	   and	   thus	   facilitates	   appetitive	  motivation,	  approach	  behavior,	  reward	  prediction,	  and	  exertion	  of	  effort.	  One	  prediction	  from	   these	   findings	   is	   that	   the	   PYY3-­‐36-­‐induced	   elevation	   of	   striatal	   dopamine	   activity	  would	  be	  associated	  with	  increased	  “wanting”	  for	  food,	  and	  consequently,	  would	  lead	  to	  increased	  food	  intake.	  But	  this	  prediction	  is	  clearly	  at	  odds	  with	  the	  numerous	  findings	  demonstrating	   reduced	   food	   intake	   following	  PYY3-­‐36	   treatment	   (Table	  1),	   even	   if	   the	  peptide	  is	  administered	  before	  subjects	  have	  access	  to	  food	  (Batterham	  et	  al.,	  2002;	  Cox	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and	  Randich,	  2004;	  Koegler	  et	  al.,	  2005).	  Consequently,	  dopamine-­‐meditated	  changes	  in	  “wanting”	   are	   unlikely	   to	   offer	   a	   plausible	   link	   between	   the	   PYY3-­‐36-­‐induced	  enhancement	  of	  striatal	  dopamine	  activity	  and	  inhibition	  of	  food	  intake.	  	   Based	  on	  the	  robust	  effects	  of	  PYY3-­‐36	  on	  central	  information	  processing	  and	  salience	  learning	  discussed	  above,	  it	  is	  tempting	  to	  hypothesize	  that	  dopamine-­‐mediated	  changes	  in	  salience	  attribution	  to	  neutral	  stimuli	  could	  contribute	  to	  the	  inhibition	  of	  food	  intake	  by	  PYY3-­‐36.	   Indeed,	   increased	   striatal	   dopaminergic	   activity	   can	  markedly	   enhance	   the	  salience	  of	  stimuli,	  even	  if	  they	  are	  neutral	  and/or	  have	  previously	  been	  associated	  with	  inconsequential	   experiences	   (Berridge	   and	   Robinson,	   1998;	   Wise,	   2004).	   A	   good	  example	   is	   the	   abolition	   of	   the	   LI	   effect	   by	   dopamine-­‐stimulating	   drugs.	   Under	  conditions	   of	   low	   dopaminergic	   activity,	   subjects	   who	   are	   pre-­‐exposed	   to	   a	   neutral	  stimulus	   (the	   CS)	   display	   slower	   conditioning	   between	   the	   CS	   and	   a	   consequential	  stimulus	   (the	  US)	  because	   they	   learn	   that	   the	  CS	   is	   a	  weak	  predictor	  of	   the	  US.	  Under	  such	  conditions,	  non-­‐reinforced	  CS	  pre-­‐exposure	  thus	  diminishes	  the	  perceived	  salience	  of	   the	   CS	   during	   conditioning	   (Mackintosh,	   1975;	   Lubow	   et	   al.,	   1981;	   Weiner,	   2003;	  Lubow,	  2005).	  Under	  conditions	  of	  high	  dopaminergic	  activity,	  however,	  the	  inhibitory	  influence	   of	   CS	  pre-­‐exposure	   on	  CS	   salience	   is	  weakened,	   so	   that	   subjects	   continue	   to	  attribute	   high	   levels	   of	   salience	   to	   the	   CS.	   As	   a	   consequence,	   CS-­‐pre-­‐exposed	   subjects	  with	  high	  dopaminergic	  activity	  behave	  as	  if	  they	  have	  not	  been	  pre-­‐exposed	  and	  go	  on	  to	   treat	   the	   CS	   as	   a	   novel	   stimulus	   that	   attracts	  much	   of	   their	   attention.	   As	   discussed	  above,	   PYY3-­‐36	   has	   a	   marked	   impact	   on	   such	   salience	   learning,	   with	   PYY3-­‐36-­‐treated	  animals	  attributing	  high	  levels	  of	  salience	  to	  previously	  pre-­‐exposed	  neutral	  stimuli.	  One	  may	  therefore	  predict	  that	  PYY3-­‐36	  administration	  before	  or	  even	  during	  access	  to	  food	  could	  alter	  salience	  or	  “attractiveness”	  of	  food	  and	  shift	  the	  subject’s	  attentive	  resources	  away	  from	  food	  to	  other	  stimuli	  that	  are	  present	  at	  the	  time	  of	  food	  intake.	  Such	  a	  shift	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may	  direct	  attention	  to	   internal	  perceptive	  processes	  or	  to	  extraneous	  external	  stimuli	  such	   as	   visual,	   auditory,	   or	   social	   cues	   that	   are	   present	   in	   the	   context	   in	   which	   food	  consumption	   occurs.	   While	   this	   hypothesis	   is	   novel	   in	   the	   context	   of	   PYY3-­‐36,	   similar	  concepts	   have	   been	   forwarded	   by	   others	   in	   other	   contexts.	   For	   example,	   it	   has	   been	  suggested	   that	  AMPH-­‐induced	   hypophagia	   is	   not	   caused	   primarily	   by	   loss	   of	   appetite,	  but	   rather	   by	   an	   altered	   brain	   state	   in	   which	   animals	   cannot	   respond	   selectively	  (Heffner	   et	   al.,	   1977;	   Cannon	   et	   al.,	   2004).	   These	   postulated	   dopamine-­‐mediated	  processes	  await	  verification.	  Moreover,	  by	  no	  means	  do	  we	  speculate	   that	   the	  PYY3-­‐36-­‐induced	   effects	   on	   food	   intake	   are	   primarily	   or	   solely	   driven	   by	   the	   peptide’s	   pro-­‐dopaminergic	  effects	  as	  gastrointestinal	  peptides	  typically	  engage	  multiple	  processes	  to	  control	   food	   intake	   (Schwartz	   et	   al.,	   2000;	   Rüttimann	   et	   al.,	   2009;	   Berthoud,	   2011;	  Woods	  and	  Ramsay,	  2011;	  Woods	  and	  Langhans,	  2012;	  Begg	  et	  al.,	  2013).	  Rather,	  our	  view	  is	  that	  the	  pro-­‐dopaminergic	  effects	  of	  PYY3-­‐36	  are	  a	  likely	  contributing	  factor	  to	  the	  inhibition	   of	   food	   intake	   and	   may	   provide	   an	   intriguing	   link	   between	   the	   peptides’	  effects	  on	  food	  intake	  and	  other	  behaviors.	  	  	  
	  
8.	  Physiological	  versus	  pharmacological	  effects	  of	  PYY3-­‐36	  One	  important	  question	  that	  remains	  to	  be	  answered	  by	  future	  investigations	  relates	  to	  the	   physiological	   relevance	   of	   the	   effects	   of	   PYY3-­‐36	   on	   behavioral	   and	   cognitive	  functions.	   It	   remains	   currently	   unknown	  whether	   the	   aforementioned	   behavioral	   and	  cognitive	  changes	  induced	  by	  peripheral	  PYY3-­‐36	  administration	  may	  primarily	  represent	  pharmacological	   effects,	   or	   alternatively,	   whether	   they	   also	   have	   physiological	  relevance.	   The	   current	   knowledge	   does	   not	   allow	   an	   evidence-­‐based	   answer	   to	   this	  question	  with	   respect	   to	  behavior	   and	   cognition.	  However,	   numerous	   findings	   in	  both	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humans	   and	   rodents	   strongly	   support	   a	   physiological	   role	   of	   PYY3-­‐36	   in	   the	   control	   of	  food	  intake.	  	  For	  example,	  genetically	  modified	  mice	  that	  lack	  PYY	  develop	  an	  obesity	  phenotype	  (Batterham	   et	   al.,	   2006;	   Boey	   et	   al.,	   2006),	   indicating	   that	   endogenous	   PYY	   signaling	  contributes	   to	  energy	  homeostasis	  and	  related	  metabolic	  processes.	  This	  hypothesis	   is	  further	   strengthened	   by	   the	   observation	   that	   obese	   individuals	   display	   attenuated	  circulating	   levels	   of	   PYY	   (Batterham	   et	   al.,	   2003;	   Chandarana	   et	   al.,	   2011).	  Moreover,	  various	   human	   and	   animal	   studies	   in	  wwhich	   exogenous	   PYY3-­‐36	  was	   administered	   in	  different	   regimens	   and	   in	   which	   post-­‐prandial	   physiological	   levels	   were	   mimicked,	  efficiently	   reduced	   food	   intake	   and	   attenuated	   body	   weight	   gain	   (reviewed	   in	  Chandarana	  and	  Batterham,	  2008;	  Kirchner	  et	  al.,	  2010).	  Another	  important	  piece	  of	  evidence	  supporting	  a	  physiological	  role	  of	  PYY3-­‐36	  in	  the	  control	  of	  food	  intake	  stems	  from	  recent	  functional	  neuroimaging	  studies	  demonstrating	  that	  physiological	   levels	   of	   PYY3-­‐36,	   besides	   activating	  homeostatic	   brain	   areas	   such	   as	  the	   hypothalamus,	   also	   activate	   numerous	   other	   cortical	   and	   subcortical	   brain	   areas,	  some	  of	  which	  play	  crucial	  roles	  in	  central	  reward	  processing	  (Batterham	  et	  al.,	  2007;	  De	  Silva	  et	  al.,	  2011;	  Weise	  et	  al.,	  2012).	  For	  example,	  Batterham	  et	  al.	  (2007)	  observed	  that	  exogenous	   PYY3-­‐36	   infusion	   in	   humans,	   which	   resulted	   in	   circulating	   PYY3-­‐36	  concentrations	  that	  were	  similar	  to	  those	  observed	  post-­‐prandially,	  modulated	  neuronal	  activity	   within	   corticolimbic	   and	   higher	   cortical	   brain	   areas,	   including	   hypothalamus,	  striatum,	   and	   orbitofrontal	   cortex.	   While	   highlighting	   extra-­‐hypothalamic	   effects	   of	  PYY3-­‐36	  at	  physiologically	  relevant	  concentrations,	  the	  data	  also	  highlight	  the	  possibility	  that	  physiological	  concentrations	  of	  PYY3-­‐36	  modulate	  behavioral	  functions	  beyond	  food	  intake.	  As	  mentioned	  above,	  however,	  the	  latter	  hypothesis	  awaits	  direct	  exploration	  by	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future	  investigations	  ascertaining	  possible	  behavioral	  and	  cognitive	  effects	  of	  exogenous	  PYY3-­‐36	  treatment	  at	  physiologically	  relevant	  concentrations.	  Related	  to	  this,	  it	  remains	  essentially	  unknown	  whether	  (physiological)	  variations	  in	  plasma	  PYY3-­‐36	  levels,	  be	  it	  after	  short-­‐term	  food	  restriction	  or	  in	  the	  post-­‐prandial	  state,	  could	  influence	  behavioral	  and	  cognitive	  functions	  such	  as	  incentive	  salience,	  short-­‐term	  memory,	  and/or	  sensorimotor	  gating.	  Most	  studies	  that	  explored	  the	  behavioral	  effects	  of	   dietary	   modulations	   such	   as	   food	   restriction	   or	   binge-­‐eating	   were	   based	   on	  experimental	  designs	  in	  which	  the	  dietary	  manipulation	  was	  chronic	  (Inoue	  et	  al.,	  2004;	  Carlini	  et	  al.,	  2008;	  Khabour	  et	  al.,	  2010;	  Labouesse	  et	  al.,	  2013).	  Under	  such	  conditions,	  the	   behavioral	   changes	   could	   readily	   be	   attributable	   to	   a	   broad	   spectrum	   of	   factors,	  including	  long-­‐term	  neuronal	  and	  neurochemical	  adaptations.	  Moreover,	  among	  the	  few	  studies	   that	   investigated	   possible	   behavioral	   modifications	   following	   short-­‐term	   food	  restriction	  (Inoue	  et	  al.,	  2004;	  McLaughlin	  et	  al.,	  2011;	  Rajab	  et	  al.,	  2014),	  none	  directly	  correlated	   the	  behavioral	   outcomes	  with	  plasma	  PYY3-­‐36	   levels.	  Therefore,	   additional	  studies	  are	  clearly	  warranted	  in	  order	  to	  explore	  whether	  (physiological)	  variations	   in	  plasma	   PYY3-­‐36	   levels	   can	   exert	   a	   significant	   influence	   of	   multiple	   behavioral	   and	  cognitive	  functions	  akin	  to	  the	  effects	  induced	  by	  peripheral	  PYY3-­‐36	  administration.	  The	  inclusion	  of	  genetically	  modified	  animals	  such	  as	  mice	  deficient	   for	  PYY	  (Batterham	  et	  al.,	  2002)	  and	  the	  Y2	  receptor	  (Baldock	  et	  al.,	  2002;	  Karl	  et	  al.,	  2010)	  may	  help	  provide	  answers	  for	  these	  open	  questions.	  Such	  attempts	  would	  also	  help	  discern	  the	  Y	  receptor	  subtypes	  that	  mediate	  the	  behavioral	  and	  cognitive	  effects	  of	  exogenous	  PYY3-­‐36	  treatment	  (Stadlbauer	  et	  al.,	  2013b,	  2014).	  Since	  PYY3-­‐36	  is	  a	  high-­‐affinity	  Y2	  receptor	  ligand	  (Walther	  et	  al.,	  2011),	  it	  is	  believed	  that	  the	  effects	  of	  peripheral	  PYY3-­‐36	  administration	  on	  behavioral	  and	  cognitive	  functions	  primarily	  involve	  signaling	  at	  the	  Y2	  receptor	  (Stadlbauer	  et	  al.,	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2013b,	  2014).	  This	  hypothesis	  would	  indeed	  be	  in	  agreement	  with	  findings	  obtained	  in	  the	  context	  of	  food	  intake:	  Mice	  deficient	  of	  the	  Y2	  receptor	  are	  resistant	  to	  the	  anorectic	  effect	  of	  exogenous	  PYY3-­‐36	  (Batterham	  et	  al.,	  2002),	  and	  pharmacological	  blockade	  of	  the	  Y2	  receptor	  using	  a	  selective	  Y2	  receptor	  antagonist	  abolishes	  the	  anorectic	  actions	  of	  PYY3-­‐36	  in	  rats	  (Abbott	  et	  al.,	  2005).	  At	  high	  concentrations,	  however,	  PYY3-­‐36	  may	  also	  bind	  to	  other	  Y	  receptor	  subtypes	  that	  are	  expressed	  in	  the	  CNS,	  including	  the	  Y1	  receptor	  (Stanic	  et	  al.,	  2011).	  It	  thus	  remains	  to	  be	  explored	  whether	  the	  effects	  of	  exogenous	  PYY3-­‐36	  treatment	  on	  incentive	  salience,	  short-­‐term	  memory,	  and	  sensorimotor	  gating	  (Stadlbauer	  et	  al.,	  2013b,	  2014)	  may	  be	  mediated	  by	  signaling	  at	  multiple	  Y	  receptor	  subclasses,	  or	  whether	  these	  may	  represent	  selective	  Y2	  receptor-­‐mediated	  effects.	  
	  
9.	  Concluding	  remarks	  Examining	  the	  effects	  of	  exogenous	  PYY3-­‐36	  in	  animal	  models	  has	  revealed	  that	  this	  gut-­‐derived	   peptide	   influences	   a	   wide	   spectrum	   of	   behavioral	   and	   cognitive	   functions.	  Hence,	   the	  behavioral	  effects	  of	  PYY3-­‐36	  are	  not	  restricted	   to	   the	  control	  of	   food	   intake	  and	  regulation	  of	  energy	  homeostasis.	  Rather,	  they	  extend	  to	  numerous	  other	  functional	  domains	   such	   as	   central	   information	   processing,	   salience	   learning,	   working	   memory,	  and	  behavioral	   responding	   to	  novelty	  and	  dopamine-­‐stimulating	  drugs.	  Whether	  PYY3-­‐
36’s	   effects	   on	   food	   intake	   and	   other	   behaviors	   are	   somehow	   interrelated	   remains	  unanswered	  and	  warrants	  further	  investigation.	  One	  intriguing	  possibility	  is	  that	  PYY3-­‐
36-­‐induced	   changes	   in	   dopaminergic	   activity	   may	   bridge	   diverse	   behavioral	  manifestations	   to	  elicit	   inhibitory	  effects	  on	   food	   intake.	  The	  continuous	   integration	  of	  behavioral	   and	   cognitive	   neuroscience	   with	   research	   on	   food	   intake	   and	   metabolism	  may	  therefore	  be	  a	  particularly	  fruitful	  approach	  to	  address	  these	  open	  questions	  as	   it	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may	   offer	   a	   heuristic	   appreciation	   of	   the	   interactions	   between	   gut-­‐derived	   signals,	  energy	  homeostasis,	  reward,	  and	  behavioral	  adaptations.	  	  	  	  	  	  
	  	  
	   	  
27	  
	  
Acknowledgements	  We	  thank	  Marie	  A.	  Labouesse	  for	  the	  stimulating	  discussions	  and	  critical	  reading	  of	  the	  manuscript.	  Related	  work	  by	  the	  authors	  has	  been	  supported	  by	  grants	  from	  the	  Swiss	  National	  Science	  Foundation	  (310030_146217,	  U.M.)	  and	  the	  ETH	  Zurich	  (47	  12-­‐2,	  W.L.).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
28	  
	  
Tables	  and	  figures	  	  
	  
Species	   Route	  of	  administration	   Food	  
intake	  
References	  
	   	   	   	  Rat	   Intraperitoneal	  (acute)	   ↓	   Batterham	  et	  al.,	  2002;	  Cox	  et	  al.,	  2004;	  Nordheim	  et	  al.,	  2004.	  Intraperitoneal	  (chronic)	   ↓	   Batterham	  et	  al.,	  2002;	  Chelikani	  et	  al.,	  2007;	  Intravenous	  (acute)	   ↓	   Chelikani	  et	  al.,	  2005;	  Stadlbauer	  et	  al.,	  2013.	  	   Subcutaneous	  (chronic)	   ↓	   Pittner	  et	  al.,	  2004.	  Mouse	   Intraperitoneal	  (acute)	   ↓	   Challis	  et	  al.,	  2003;	  Halatchev	  et	  al.,	  2005;	  Martin	  et	  al.,	  2004;	  Pittner	  et	  al.,	  2004.	  Subcutaneous	  (chronic)	   ↓	   Pittner	  et	  al.,	  2004.	  Non-­‐human	  primates	   Intramuscular	  (acute)	   ↓	   Moran	  et	  al.,	  2005.	  Intravenous	  (acute)	   ↓	   Koegler	  et	  al.,	  2005.	  Human	   Intravenous	  (acute)	   ↓	   Batterham	  et	  al.,	  2002;	  Degen	  et	  al.,	  2005;	  le	  Roux	  et	  al.,	  2008.	  
	  








	  	  	  





Figure	  3.	  Proposed	  model	  by	  which	  PYY3-­‐36	  induces	  hyperdopaminergic	  states	  in	  striatal	  areas.	   GABAergic	   interneurons	   (green)	   located	   in	   the	   striatum	   (Str)	   tonically	   inhibit	  striatal	   dopamine	   terminals	   (red).	   Activation	   of	   GABA	   receptors	   on	   dopamine	   fibers	  causes	   chloride	   ion	   (Cl-­‐)	   influx	   and	   consequently	   results	   in	   hyperpolarization	   of	  presynaptic	  dopamine	  terminals.	  PYY3-­‐36-­‐induced	  activation	  of	  Y2	  receptors	   located	  on	  striatal	  GABAergic	  interneurons	  reduces	  the	  neural	  activity	  of	  GABAergic	  cells,	  which	  in	  turn	  weakens	  their	  inhibitory	  inputs	  onto	  presynaptic	  dopamine	  terminals.	  The	  PYY3-­‐36-­‐induced	  attenuation	  of	  this	  fast-­‐forward	  inhibitory	  mechanism	  facilitates	  the	  release	  of	  dopamine	  (as	  indicated	  by	  the	  black	  arrows).	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